Edinburgh, United Kingdom
Edinburgh, United Kingdom
SEARCH FILTERS
Time filter
Source Type

News Article | April 19, 2017
Site: tech.eu

Scottish Synpromics Ltd, a gene control company, has raised £5.2 million. The funding comes from existing investors Calculus Capital, the Scottish Investment Bank, the investment arm of Scottish Enterprise, and private shareholders. Synpromics develops synthetic promoters - DNA sequences that do not exist in nature, and are designed to regulate the activity of genes. Currently, the biotech industry relies mostly on naturally occurring promoters, however Synpromics has developed technology that allows for the design of synthetic promoters to customize gene regulation at the desired level of specificity. The company says its technology gives biological researchers, developers and manufacturers unprecedented control of gene expression through by creating a portfolio of man-made DNA regulatory sequences. The company says it will use the majority of the new investment to further develop its PromPT™ synthetic promoter design platform. PromPT™ enables the design of unique synthetic promoters which give precise control of gene function in many areas of gene medicine including gene therapy, cell therapy and gene editing. The company is also preparing to move into a larger facility. Synpromics has expanded over the past two years, attracting international customers including gene therapy companies and multinational technology corporations, most recently GE Healthcare. “Since our last fundraising round 18 months ago the business has grown rapidly as we’ve signed more commercial partnerships with companies in the US and Europe," said David Venables, CEO of Synpromics, in a statement. "We see an exciting opportunity to fund further rapid expansion of our business, supported by our innovative science and novel capabilities.” “We have been delighted with the progress which Synpromics has made since we made our first investment some 18 months ago," added Alexandra Lindsay, Investment Director at Calculus Capital. "They have a very strong team and the technology has been clearly validated through partnerships with some of the world’s leading gene medicine companies.”


News Article | September 11, 2017
Site: www.businesswire.com

EDINBURGH, Scotland--(BUSINESS WIRE)--Synpromics Ltd, the leader in gene control and synthetic promoter development, today moves to new world-class facilities at the Roslin Innovation Centre. Synpromics is expanding to meet increasing global demand for its cutting-edge gene control technology, and is the first company to move into the new custom-built centre based at the University of Edinburgh’s Easter Bush Campus. David Venables, CEO of Synpromics, explained, “Our move to Roslin is the result of two incredibly successful years for the company. In 2017 alone, we’ve signed gene therapy deals with a large, orphan disease pharma company and most recently with a US biotech specialising in gene editing and developing rare disease gene therapies. We’ve also signed bioprocessing deals with a top-10 pharma company and a global CDMO. Currently, the company has over ten active commercial gene therapy programmes and five bioprocessing programmes underway. Over that time Synpromics’ team has grown by over 100% and is one of our greatest assets. We look forward to working in our new high tech facilities as we continue to build the company for the future.” CSO and founder of Synpromics, Dr Michael Roberts, added that “the company’s recent successes have been greatly accelerated by our revolutionary PromPT™ technology. PromPT™ is our unique bioinformatics engine, the culmination of over 10 years’ work, to enable data-driven synthetic promoter design. It has been hugely important in helping us build an extensive IP portfolio, for both our partners and ourselves, and is of substantial commercial value. We are particularly pleased with the suite of tightly regulated inducible promoters that we have created using our platform, and the excitement they generated at The Bioprocessing Summit in Boston this year”. Dr John Brown, Chairman of Synpromics, also announced today that the company is expanding its Board. “We’re delighted to welcome Dr Alan Lamont to Synpromics as a non-executive director. Alan has extensive experience that will be extremely valuable to us as we grow. He’s held senior corporate and business development roles with leading UK and US companies including Acambis, AstraZeneca, Eli Lilly and Mundipharma International”. The Roslin Innovation Centre is a multi-purpose building offering 41,000sq ft of flexible laboratory and office space. Synpromics will occupy both labs and open plan offices at the new facility. John Mackenzie, CEO of Roslin Innovation Centre, said, “Synpromics, as one of the UK’s most innovative companies working in gene medicine, is an ideal fit for our profile. Synpromics’ innovation has been attracting attention within the life sciences community and we look forward to providing an environment conducive for the business to realise its long-term growth ambition.” Synpromics is the leader in gene control, improving human health by enabling safer, more effective cell and gene medicines through proprietary genomics, bioinformatics and intelligent data-driven design. The Company has developed PromPT™, its multi-dimensional bioinformatics database that enables product-specific promoter design and selection empowering the next generation of cell and gene based medicines and bioprocessing applications. The company operates in a diverse range of fields, including broad applications in cell and gene based medicine, biologics manufacturing and viral vector bioprocessing. Current partners include Adverum, uniQure, AGTC, GE Healthcare, and Sartorius-Stedim Cellca as well as numerous undisclosed partners in the pharmaceutical sector. Naturally occurring promoters have evolved for biological functions but have limitations when utilised in industrial or therapeutic applications. Synthetic promoters with DNA sequences not found in nature are designed to better regulate gene activity and precisely control protein production. Synpromics creates highly specific promoters designed to drive gene expression at the desired level and specificity in any cell type, tissue or environmental condition. Each synthetic promoter represents a novel invention and thus can be patented.


News Article | September 20, 2017
Site: www.businesswire.com

EDINBURGH, Scotland--(BUSINESS WIRE)--Synpromics Ltd, the leader in gene control, today announces a new research partnership with Solid Biosciences, LLC. Under the terms of the agreement, Synpromics will provide Solid Biosciences access to a set of key muscle-selective promoter candidates to be used in the development of new treatment options for Duchenne muscular dystrophy (DMD). The use of Synpromics’ synthetic promoters will enable the enhancement of Solid Biosciences’ investigational gene therapy candidates for the treatment of DMD. These muscle-selective promoters have been designed using Synpromics’ PromPT® technology and bioinformatics expertise, and will be evaluated by Solid Biosciences for optimal product specific gene control. “We are excited to leverage our PromPT® technology platform to generate promoter candidates closely matching the precise criteria and specific product requirements for Solid Biosciences’ muscle gene medicine programme in Duchenne,” David Venables, CEO of Synpromics, commented. “The collaboration between the scientific teams will enable the effective and rapid in vivo evaluation of the candidate promoters as compared to industry standards.” “Synpromics’ cutting-edge technology has the potential to enhance our gene therapy development efforts, helping us to fulfil our promise to bring meaningful therapies to all patients with this devastating disease,” said Joel Schneider, PhD, Chief Technology Officer, Head of Exploratory R&D at Solid Biosciences. “This type of collaboration is key for building our next-generation gene therapy portfolio as we focus on enhancing fundamental aspects of our gene delivery and protein expression capabilities.” Duchenne muscular dystrophy (DMD) is a genetic muscle-wasting disease that is progressive, irreversible and ultimately fatal. DMD affects approximately one in every 3,500 to 5,000 live male births. Symptoms of DMD usually manifest between three to five years of age. As the disease progresses, patients are typically wheelchair-bound by their early teens and succumb to respiratory or heart failure in early adulthood. There is no cure for DMD and, for the vast majority of patients, there are no satisfactory treatments. This research collaboration will help advance Solid’s programme to develop optimal product candidates for the company’s AAV muscle-directed gene therapy research programme. Synpromics is the leader in gene control, improving human health by enabling safer, more effective cell and gene medicines through proprietary genomics, bioinformatics and intelligent data-driven design. The company has developed PromPT®, its multi- dimensional bioinformatics database that enables product-specific promoter design and selection empowering the next generation of cell and gene based medicines and bioprocessing applications. The company operates in a diverse range of fields, including broad applications in cell and gene based medicine, biologics manufacturing and viral vector bioprocessing. Current partners include Adverum, uniQure, AGTC, GE Healthcare, Homology Medicines, Inc and Sartorius-Stedim Cellca as well as numerous undisclosed partners in the pharmaceutical sector. Naturally occurring promoters have evolved for biological functions but have limitations when utilised in industrial or therapeutic applications. Synthetic promoters with DNA sequences not found in nature are designed to better regulate gene activity and precisely control protein production. Synpromics creates highly specific promoters designed to drive gene expression at the desired level and specificity in any cell type, tissue or environmental condition. Each synthetic promoter represents a novel invention and thus can be patented. For more information visit www.synpromics.com


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Feasibility Study | Award Amount: 241.60K | Year: 2013

Enhancing methods of protein expression is fundamentally important to new drug development and the efficient production of biopharmaceuticals. The consortium aims to develop a novel means of designing and constructing synthetic promoters that can be employed on an industrial scale to drive the expression of proteins for commercial applications. This will be achieved by combining the synthetic promoter design capabilities of Synpromics with improved DNA assemble methodology from Genabler and systems biology expertise from the SynthSYS institute of the University of Edinburgh. The project will yield a novel platform technology that can be used to create synthetic promoters with multiple applications across the biotech sector. This initial feasibility study will incorporate disparate expertise from the three partners to construct synthetic promoters that can enhance the production of proteins in mammalian cell culture systems, with a view to improve upon protein yield and quality.


Patent
Synpromics Ltd | Date: 2012-07-25

The present application relates to a system for designing promoters for selective expression of genes. Thereby identified transcription regulatory elements are selected according to a specific methodology and used to create a library of transcription regulatory elements, which are then used to construct specific promoters, especially tissue-specific promoters.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 1.58M | Year: 2016

Evolving therapeutic approaches of cell and gene therapy are harnessing the power of viruses in order to modify genomes of cells to produce a therapeutic effect. Such therapies are starting to show efficacy in the clinic, but one of the key challenges to their widespread use is the ability to make large quantities of virus at a low cost. This project seeks to address this challenge by creating new methods of producing large quantities of virus at a low cost. It brings together Synpromics, a synthetic biology company based in Edinburgh, and the Cell Therapy Catapult, one of the UK’s network of Catapult centres focused on developing and growing a cell and gene therapy industry in the UK.


Patent
Synpromics Ltd | Date: 2012-01-25

The present application relates to a system for designing promoters for selective expression of genes. Thereby identified transcription regulatory elements are selected according to a specific methodology and used to create a library of transcription regulatory elements, which are then used to construct specific promoters, especially tissue-specific promoters.


Trademark
Synpromics Ltd | Date: 2016-12-21

Biological materials including genetic constructs, especially synthetic promoters and vectors; nucleic acids; materials for the construction of genetic constructs, especially synthetic promoters and vectors; cells, viruses and other carriers including such genetic constructs. Biological preparations for medical purposes; biological preparations for veterinary purposes. Agricultural, aquacultural, horticultural and forestry products; seeds; natural plants and flowers; propagation material. Biotechnological research and development services, including: design and provision of biological materials including genetic constructs, especially synthetic promoters and vectors; cells, viruses and other carriers including such genetic constructs; analysis and profiling of gene expression; technical information services in relation to the aforesaid and in respect of the construction of genetic constructs, especially synthetic promoters and vectors.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 207.83K | Year: 2014

The collaboration between Synpromics Ltd. and Touchlight Genetics Ltd. will combine two highly innovative and complementary technology platforms to develop an improved approach to developing DNA vaccines. The project will leverage Synpromicss proprietary technology to rationally design synthetic promoters that drive cell-specific antigen expression and that enhance the effectiveness of Touchlight Genetics’s unique synthetic DNA vaccine cassette platform. The resulting new technology will subsequently be applied by Touchlight Genetics in the company’s internal DNA vaccine develoment programs, as well as be available for licensing by other developers. The project is expected to establish a unique UK-based synthetic biology capability for the production of safer and more effective DNA-based medicines.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 289.78K | Year: 2014

The collaboration between Synpromics and Ingenza is focused on developing proprietary protein production systems in engineered yeast strains that improve on currently available alternatives by incorporating novel synthetic promoter constructs rationally designed to drive optimal gene expression. The enabling technology that the project aims to deliver will address significant limitations faced by a wide range of bio-manufacturers using yeast-based expression, enabling the more efficient production of protein products and intermediary production enzymes. The combination of Synpromicss and Ingenzas innovative technologies and expertise is expected to validate a platform on which to build an even broader range of solutions to yeast-based expression challenges, thereby establishing in the UK a leading capability in synthetic biology and sustainable industrial bioprocessing.

Loading Synpromics Ltd collaborators
Loading Synpromics Ltd collaborators